Navigation Links
Cheaper drugs, vaccines forecast as collaborations grow between developing countries' biotech firms
Date:5/10/2010

ountries as well as seven developed countries.

As a result nimotuzumab has been approved as a treatment for head and neck cancers and glioma, in 23 countries worldwide including Argentina, Brazil, China, India, Indonesia, Mexico and Ukraine. The consortium members license the drug from CIMAB and market it in their home countries. By including a south-south collaboration strategy, biotech firms can bypass pharma companies, retain greater presence in latter stages of the product's development, and potentially have a greater share of the revenues.

Vaccines for Africa's meningitis outbreak

To counter a meningitis outbreak in 2007 the World Health Organization (WHO) identified Bio-Manguinhos (Rio de Janeiro, Brazil), in collaboration with the Finlay Institute (Havana, Cuba), as the most suitable suppliers of a meningitis vaccine. They relied on their respective strengths in the development and manufacturing process and neither firm alone would have been able to respond so quickly and efficiently to this request. This shows how south-south collaboration can be harnessed to address a health threat spurred by demand and funding from an international organization.

South- South approach to dealing with HIV/AIDs based on local biodiversity

China and Thailand are working together to develop a remedy against HIV/AIDs based on Chinese biodiversity and knowledge from traditional Chinese medicine. After extensive animal testing in China, clinical trials began in Thailand where the incidence of HIV/AIDS is far higher. The herbal-based anti HIV drug -- Complex SH -- is the first to ever undergone Phase I, II, and III clinical trials. Complex SH is said to inhibit growth of HIV and kill the virus and has an efficacy rate of 89% when used alone, and even higher with other therapies. And all without the side effects that accompany a similar class of biomedical drugs.

The product is patented and has received regulator
'/>"/>

Contact: Terry Collins
terrycollins@rogers.com
416-538-8712
McLaughlin-Rotman Centre for Global Health
Source:Eurekalert

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Hybrid computer materials may lead to faster, cheaper technology
2. Cheaper materials could be key to low-cost solar cells
3. Stanford researchers find a quicker, cheaper way to sort isotopes
4. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
5. Amazing Treatment Relieves Serious Back Pain Without Dangerous Drugs, Injections or Surgery!
6. New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents
7. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
8. Emergence of Cancer Vaccines Will Be the Key Factor Driving the Pancreatic Cancer Drug Market to More Than Double by 2016
9. Vaccines are Likely to Cause Insulin Dependent Diabetes in Over 2% of Children With a Strong Family History of Insulin Dependent Diabetes, New Data Indicates
10. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
11. PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE MKT: ... of biosimilar therapeutics, today announced that it will be ... Marquis on March 2 nd at 3pm PST. Patrick ... a panel discussing the current state of the biosimilar ... . For more information on CALBIO ...
(Date:2/26/2015)... NEW YORK , Feb. 26, 2015 ... commenced Factual Stock Report coverage on MabVax Therapeutics ... Inc. (MBVX) is a clinical stage biotechnology company focused ... address unmet medical needs in the treatment of cancer. ... products based on the protective immune responses generated by ...
(Date:2/26/2015)... , Feb. 26, 2015   Regulus Therapeutics ... company leading the discovery and development of innovative medicines ... , Ph.D., President and Chief Executive Officer of Regulus, ... Company 35 th Annual Healthcare Conference on Wednesday, ... is being held at the Boston Marriott Copley Place.  ...
(Date:2/26/2015)... 2015  NuGene International, Inc. ("NuGene") (OTCQB: NUGN), ... and hair rejuvenation, has announced that it has ... for investor relations and strategic communications. ... and diversification strategies – and we need to ... stated Ali Kharazmi CEO of NuGene when announcing ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3
... Company, FRAZER, Pa., Feb. 8 Cephalon, Inc., ... Counsel &,Secretary, John E. Osborn, has decided to resign ... has agreed to remain as an advisor,to the company ... been an invaluable member of our senior executive team ...
... REDWOOD CITY, Calif., Feb. 8 Genomic Health,Inc. (Nasdaq: ... Health,s,President and Chief Operations Officer, will present at the ... Feb. 12, 2008 at 10:15 a.m. Eastern,Time., To ... visit the Investor Relations section of Genomic Health,s,website at ...
... InterMune, Inc.,(Nasdaq: ITMN ) today announced results from operations ... company also provided 2008,financial guidance and milestones for its key ... InterMune reported a net loss for the fourth quarter of ... net loss of $21.5 million, or,$0.64 per share, in the ...
Cached Biology Technology:Cephalon General Counsel John E. Osborn to Resign Position 2Cephalon General Counsel John E. Osborn to Resign Position 3InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 2InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 3InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 4InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 5InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 6InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 7InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 8InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 9InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 10InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 11
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... SAN DIEGO , Jan. 26, 2015   Epic ... treatment of cancer, today announced that Murali Prahalad , ... Personalized Medicine World Conference (PMWC) 2015: Silicon Valley, ... Mountain View, Calif. on January 26-28, ... entitled, "CTCs Come of Age as Biomarkers." Last year, Epic ...
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... date of 130 North American tree species concludes that ... northward by hundreds of kilometers and shrink the ranges ... McKenney of the Canadian Forest Service and his colleagues, ... McKenneys study is based on an extensive data-gathering effort ...
... Trust researchers have identified a key gene involved in the ... mostly women. The lead researcher behind the study has called ... to further study the underlying causes of the disease. ... autoimmune disease which frequently causes skin rash, joint pains and ...
... able to differentiate metastatic cancer cells from normal cells ... softness of the cells. The study, published Dec. ... journal Nature Nanotechnology, represents one of the first times ... cancer patients and apply nanotechnology to analyze them and ...
Cached Biology News:Climate change predicted to drive trees northward 2Lupus gene finding prompts call for more DNA samples 2Using nanotechnology, UCLA researchers discover cancer cells 'feel' much softer than normal cells 2Using nanotechnology, UCLA researchers discover cancer cells 'feel' much softer than normal cells 3Using nanotechnology, UCLA researchers discover cancer cells 'feel' much softer than normal cells 4
Identify and characterize Phosphoinositide (PI(3,4,5)P3) binding...
Anti-Human alpha2-Antiplasmin Purified (Polyclonal) (goat IgG)...
Volume adapter mounts on top of the 96 well FiltrEX filter plate and allows larger volumes (1mL) to be applied to each well in a filter plate. Adapters are nonsterile....
... The Mini-PROTEAN 3 Dodeca cell with multi-casting chamber ... up to 12 mini format handcast (8.3 x ... gels. The cell requires 3.4-4.4 L of buffer ... coil that attaches to an external refrigerated circulator ...
Biology Products: